Close Menu

NEW YORK – TargetCancer Foundation said on Wednesday that it initiated the TCF-001 TRACK study, a prospective clinical trial that will enroll 400 patients with rare cancers such as cholangiosarcoma or cancers of unknown primary.

TargetCancer Foundation is the study's sponsor, and Bayer is also a founding supporter. Roche subsidiary Foundation Medicine, which markets tissue and blood-based next-generation sequencing panels for guiding cancer treatment, is also a collaborator.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.